Catalent today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer.
Catalent today announced a collaboration with Johnson & Johnson for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.
Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
Catalent today announced the appointment of Manja Boerman, Ph.D., to the role of President, Cell & Gene Therapy. In this new role, Dr. Boerman will lead all of Catalent’s cell & gene therapy businesses worldwide.
SOMERSET, N.J., October 4, 2018 – Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, …
